NCT04556500 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Carl G, Priscila M, Cacola
A New Inventory For Assessing Affordance in the Home environment For Motor Development. Early Childhood Edu J 2008;36(1):5-9.
Hwang AW, Liao HF, Granlund M, Simeonsson RJ, Kang LJ, Pan YL
Linkage of ICF-CY codes with environmental factors in studies of developmental outcomes of infants and toddlers with or at risk for motor delays. Disabil Rehabil. 2014;36(2):89-104. doi: 10.3109/09638288.2013.777805. Epub 2013 Apr 17. Review.

Psychometric Properties of the Turkish Version of the Affordance in the Home Environment for Motor Development-Toddler (AHEMD-T)

Clinical trial NCT04556500 - References